Tg therapeutics, inc. (TGTX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
CASH FLOWS FROM OPERATING ACTIVITIES
Consolidated net loss

-188,831

-172,871

-187,159

-187,785

-167,109

-173,482

-150,482

23,276

-132,278

-118,476

-111,290

-104,586

-92,131

-78,253

-72,190

-61,015

-62,219

-62,948

-64,133

-67,928

-62,811

-55,781

-42,648

-29,753

-24,351

-20,478

-18,316

-16,470

-12,460

-26,182

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Gain on settlement of notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

95

95

95

95

0

0

0

0

-

-

-

-

Non-cash stock compensation expense

0

-

0

0

0

-

0

0

0

-

0

0

11,806

-

9,038

7,444

12,039

15,697

17,878

20,735

22,230

21,105

17,014

13,914

7,549

5,203

5,499

5,320

5,119

3,422

0

0

0

Shares issued in connection with in-licensing agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

16,578

0

0

0

Impairment of in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,104

1,104

0

0

0

Depreciation and amortization

107

100

96

93

91

88

84

82

82

82

82

80

76

63

47

32

19

15

11

8

5

3

2

2

1

1

0

0

0

0

0

0

0

Amortization of premium on investment securities

226

257

-39

-21

192

119

-44

7

32

61

145

249

361

459

526

584

583

536

444

332

258

193

128

67

16

0

0

0

0

-

-

-

-

Reclassification of deferred financing costs to additional paid-in capital

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt issuance costs

954

800

500

300

77

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Amortization of leasehold interest

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash change in lease liability and right-of-use asset

4,147

2,519

1,921

902

373

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of notes payable

-38

-124

126

57

91

61

17

107

-49

-59

-66

-64

-54

110

27

167

112

56

1

-136

-156

-210

2,085

2,205

2,308

2,414

741

660

870

815

0

0

0

Changes in assets and liabilities:
Decrease (increase) in prepaid research and development and other current assets

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4

4

4

4

578

577

576

575

0

0

0

-

-

-

-

-

-

-

-

Increase in other current assets

0

-

-

-

0

-

-

-

-

2,665

-4,875

-5,013

-2,230

-3,565

212

3,689

1,197

3,105

1,032

7,296

7,733

4,563

8,946

3,422

178

-229

-1,354

662

2,521

1,932

0

0

0

Decrease in leasehold interest

-

-

-

-

-

-

-

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Increase in accrued interest receivable

-15

11

-42

-26

2

-14

137

88

56

25

-108

-90

-141

-102

-50

-56

74

100

104

115

78

58

53

74

11

27

0

0

0

-

-

-

-

Decrease in other assets

-

-

-

-

-

-

-

-

-

-162

-160

-399

-231

5

45

51

62

41

13

-13

-17

0

-98

-76

-8

0

0

0

0

-

-

-

-

(Decrease) increase in accounts payable and accrued expenses

-8,602

-4,795

-5,201

-3,529

7,905

10,957

20,675

16,850

13,760

11,020

2,711

5,848

10,620

6,493

7,260

5,164

-539

5,470

785

6,417

7,719

-603

3,891

-185

-94

4,034

2,503

900

1,091

595

0

0

0

Decrease in lease liabilities

-3,176

-1,548

-1,129

-678

-339

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Decrease) increase in interest payable

110

1,491

787

443

549

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-94

-77

-60

-43

66

65

63

62

61

0

0

0

Decrease in other liabilities

10,471

28,810

43,001

20,738

17,791

18,350

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase in deferred rent

-

-

-

-

-

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Decrease in deferred revenue

-152

-152

-152

-152

-152

-152

-152

-152

-152

-152

-151

-151

-151

-152

-152

-152

-152

-152

-152

-152

-152

-152

-152

-152

-152

-152

1,866

1,904

1,942

1,980

0

0

0

Net cash used in operating activities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net cash used in operating activities

-

-

-

-

-

-

0

0

-99,502

-

-88,925

-81,192

-67,214

-61,587

-57,466

-53,083

-52,481

-44,690

-46,896

-44,288

-35,613

-35,059

-24,777

-17,880

-16,863

-10,739

0

0

0

-

-

-

-

CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from maturity of short-term securities

31,200

29,250

29,400

31,600

33,550

32,500

25,600

23,200

19,800

19,800

36,710

25,500

26,500

29,500

23,089

31,500

29,500

24,350

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Investment in held-to-maturity long-term securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Investment in held-to-maturity securities

0

-

-

0

0

-

-

34,971

32,190

28,006

0

0

4,558

15,200

23,238

29,122

59,634

48,993

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of equipment

185

131

103

64

80

90

84

58

26

2

22

35

61

344

306

331

317

42

73

35

22

18

6

7

8

5

3

1

1

1

0

0

0

Financing costs paid

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturity of short-term securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Cash acquired in connection with acquisition

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Net cash provided by (used in) investing activities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net cash (used in) provided by investing activities

-

-

-

-

-

-

0

0

-12,416

-

31,276

38,052

34,468

26,545

17,544

2,045

-30,452

-24,685

-36,297

-36,375

-14,509

-18,355

-14,144

-14,145

-4,928

-4,925

0

0

0

-

-

-

-

CASH FLOWS FROM FINANCING ACTIVITIES
Payment of notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

677

677

677

677

0

0

0

0

-

-

-

-

Proceeds from sale of common stock, net

-

175,021

81,358

65,151

88,887

113,639

123,683

147,407

99,180

131,516

117,684

89,468

89,177

4,411

3,504

19,279

32,819

67,760

93,816

100,807

83,336

65,614

0

0

0

-

-

-

-

-

-

-

-

Proceeds from exercise of options

0

-

-

-

-

-

-

-

-

2,143

2,660

2,710

2,738

618

158

124

681

1,067

1,676

2,947

3,063

3,556

3,173

2,159

2,245

2,280

1,997

1,723

936

0

0

0

0

Proceeds from debt financings

-

29,987

29,675

29,679

29,740

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financing costs paid

-

-

-

-

0

-

-

-

-

-

-

-

-

13

45

88

92

104

120

71

71

51

0

0

0

-

-

-

-

-

-

-

-

Payments of short-term loans

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

200

0

0

0

Proceeds from sale of common stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Proceeds from sale of preferred stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

12,257

0

0

0

Offering costs paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

55

75

0

0

0

Purchase of treasury stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

84

84

0

0

0

Net cash provided by financing activities

-

-

-

-

-

-

0

0

99,180

-

120,341

92,170

91,910

5,016

3,616

19,316

33,407

68,723

95,429

103,885

86,530

68,643

41,964

55,686

56,200

39,694

0

0

0

-

-

-

-

Net cash provided by financing activities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

-12,289

70,689

-26,034

-48,435

-17,891

-14,106

-20,471

28,722

-12,738

31,691

62,692

49,030

59,164

-30,026

-36,305

-31,722

-49,526

-652

12,236

23,222

36,408

15,228

3,042

23,661

34,408

24,029

32,809

-6,950

-5,735

6,707

0

0

0

NONCASH TRANSACTIONS
Accrued offering costs

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of notes payable to preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Deferred financing costs

-

-

-

-

-

-

0

0

0

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-55

0

0

0

0

Warrants issued with debt financing

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-